CPBI
Central Plains Bancshares, Inc. Common Stock
There isn't enough reported data to score CPBI yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
CPBI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
CPBI's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CPBI.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CPBI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $19.23 | -7.2% |
| Fair | 17x | $20.27 | -2.2% |
| Expensive | 18x | $21.33 | +2.9% |
| Current | 18x | $20.73 | — |
Historical ranges are pointers, not guarantees.
CPBI has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
CPBI Forward outlook
There aren't enough analyst estimates for CPBI to show an outlook.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
CPBI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $1.18 | +20% |
| Q1 2026 | $1.05 | +9.4% |
CPBI's earnings per share have climbed steadily: $1.18 over the past year, up 20% from the year before, and higher year over year every quarter since early 2026.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over CPBI in the latest year-over-year earnings comparison.
CPBI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.3M | +15% |
| Q1 2026 | $7.8M | +9.1% |
| Q4 2025 | $7.9M | +14% |
| Q3 2025 | $7.5M | +10% |
| Q2 2025 | $7.2M | +11% |
| Q1 2025 | $7.1M | +12% |
| Q4 2024 | $6.9M | +9% |
| Q3 2024 | $6.8M | +19% |
CPBI's revenue has grown year over year every quarter since late 2023: $8M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 22% | +5.2 points |
| Q1 2026 | 15% | +0.1 points |
| Q4 2025 | 19% | +1.5 points |
| Q3 2025 | 15% | -2.1 points |
| Q2 2025 | 17% | 0 points |
| Q1 2025 | 15% | -1.9 points |
| Q4 2024 | 17% | -1 points |
| Q3 2024 | 17% | -4.5 points |
CPBI's operating margin was 22% last quarter, up 5.2 points from the same quarter a year ago, near the top of its range since 2023.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over CPBI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over CPBI on profitability, with a higher operating margin.
CPBI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$200K | +$566K |
| Q1 2026 | $3.5M | +$4.1M |
| Q4 2025 | $2.2M | +$3.7M |
| Q3 2025 | $888K | +$1.9M |
| Q2 2025 | -$766K | -2289% |
| Q1 2025 | -$647K | -$381K |
| Q4 2024 | -$1.5M | -165% |
| Q3 2024 | -$975K | -435% |
CPBI has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CPBI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +10.2K shares |
| 1 year | +0.5% | +17.2K shares |
| 3 years | -7.5% | -310K shares |
CPBI has 4M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $296,000 |
| Q1 2026 | $135,000 |
| Q4 2025 | $194,000 |
| Q3 2025 | $90,000 |
| Q2 2025 | $260,000 |
| Q1 2025 | $276,000 |
| Q1 2023 | — |
| Q4 2022 | — |
CPBI spent $715,000 buying back its own shares over the past year.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over CPBI on shareholder dilution, with a more favorable share count trend.
CPBI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -5.2x | Net Cash |
| Q1 2026 | -5.0x | Net Cash |
| Q4 2025 | -4.9x | Net Cash |
| Q3 2025 | -1.7x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -5.8x | Net Cash |
| Q4 2024 | -1.3x | Net Cash |
| Q3 2024 | -2.0x | Net Cash |
CPBI has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
CPBI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.6 | Neutral |
| Stochastic | 68.0 | Neutral |
CPBI's weekly RSI is 62 (neutral) and its Stochastic is 68 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CPBI PE vs Financial Services Sector
| Metric | CPBI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 13x | 35% above |
| PE % | 63 | 41 | 22 pts above |
CPBI is trading at 18x earnings, a 35% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS has the edge over CPBI on valuation relative to its sector.
CPBI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 1.9% above |
| 20 week MA | $20.5 | 1.4% above |
| 50 week MA | $18.7 | 11% above |
| 100 week MA | $17.0 | 22% above |
CPBI has stronger trend alignment. CPBI is above 4 of 4 weekly averages versus MS above 3 of 5.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CPBI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $9.10 | $10.2 | +12% |
| 2024 | $10.2 | $14.4 | +41% |
| 2025 | $14.4 | $16.9 | +17% |
| 2026 YTD | $16.9 | $20.7 | +22% |
CPBI has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.